Daniel Bradbury Sells 23,323 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 23,323 shares of Castle Biosciences stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $24.64, for a total value of $574,678.72. Following the transaction, the director now directly owns 9,981 shares in the company, valued at $245,931.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Daniel Bradbury also recently made the following trade(s):

• On Monday, April 8th, Daniel Bradbury sold 2,400 shares of Castle Biosciences stock. The stock was sold at an average price of $20.45, for a total value of $49,080.00.
• On Thursday, April 4th, Daniel Bradbury sold 9,152 shares of Castle Biosciences stock. The shares were sold at an average price of $21.45, for a total transaction of $196,310.40.
• On Monday, March 4th, Daniel Bradbury sold 23,323 shares of Castle Biosciences stock. The shares were sold at an average price of $20.68, for a total transaction of $482,319.64.

Castle Biosciences Price Performance

Shares of CSTL opened at $24.42 on Friday. The business’s 50-day moving average is $20.81 and its two-hundred day moving average is $20.61. The company has a market capitalization of $674.24 million, a P/E ratio of -21.23 and a beta of 0.93. Castle Biosciences, Inc. has a fifty-two week low of $9.26 and a fifty-two week high of $26.70. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.02 and a current ratio of 9.25.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.74. The firm had revenue of $66.12 million for the quarter, compared to the consensus estimate of $51.32 million. Castle Biosciences had a negative net margin of 12.28% and a negative return on equity of 7.91%. Research analysts predict that Castle Biosciences, Inc. will post -2.41 earnings per share for the current year.

Hedge Funds Weigh In On Castle Biosciences

A number of hedge funds have recently made changes to their positions in CSTL. BluePath Capital Management LLC purchased a new stake in shares of Castle Biosciences in the third quarter valued at approximately $31,000. RiverPark Advisors LLC grew its holdings in Castle Biosciences by 362.2% in the 1st quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock valued at $63,000 after buying an additional 2,242 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Castle Biosciences by 34.2% during the 3rd quarter. Assetmark Inc. now owns 3,904 shares of the company’s stock worth $66,000 after acquiring an additional 994 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Castle Biosciences by 351.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,110 shares of the company’s stock valued at $67,000 after purchasing an additional 2,421 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Castle Biosciences by 74.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,797 shares of the company’s stock worth $115,000 after purchasing an additional 2,909 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CSTL. Robert W. Baird lifted their target price on Castle Biosciences from $33.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. KeyCorp lifted their price objective on shares of Castle Biosciences from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, March 1st. Finally, Scotiabank upped their target price on shares of Castle Biosciences from $33.00 to $37.00 and gave the stock a “sector outperform” rating in a research note on Friday, March 1st.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.